EA202092540A1 - Комбинации для лечения рака - Google Patents

Комбинации для лечения рака

Info

Publication number
EA202092540A1
EA202092540A1 EA202092540A EA202092540A EA202092540A1 EA 202092540 A1 EA202092540 A1 EA 202092540A1 EA 202092540 A EA202092540 A EA 202092540A EA 202092540 A EA202092540 A EA 202092540A EA 202092540 A1 EA202092540 A1 EA 202092540A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
cancer treatment
acceptable salt
pharmaceutically
pentaazaheptacyclo
Prior art date
Application number
EA202092540A
Other languages
English (en)
Russian (ru)
Inventor
Скотт Бойко
Джастин Сидадо
Лиза Дрю
Тереза Пройа
Марианн Сан Мартин
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA202092540A1 publication Critical patent/EA202092540A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA202092540A 2018-04-30 2019-04-29 Комбинации для лечения рака EA202092540A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
EA202092540A1 true EA202092540A1 (ru) 2021-03-17

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092540A EA202092540A1 (ru) 2018-04-30 2019-04-29 Комбинации для лечения рака

Country Status (14)

Country Link
US (1) US20210030718A1 (cg-RX-API-DMAC7.html)
EP (1) EP3787620A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021522246A (cg-RX-API-DMAC7.html)
KR (1) KR20210005182A (cg-RX-API-DMAC7.html)
CN (1) CN112040944A (cg-RX-API-DMAC7.html)
AU (1) AU2019263026B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3097486A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092540A1 (cg-RX-API-DMAC7.html)
MA (1) MA52499A (cg-RX-API-DMAC7.html)
MX (1) MX2020011453A (cg-RX-API-DMAC7.html)
SG (1) SG11202010528XA (cg-RX-API-DMAC7.html)
TW (1) TW202014184A (cg-RX-API-DMAC7.html)
WO (1) WO2019211721A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4054582T3 (da) 2019-11-04 2025-12-01 Astrazeneca Ab Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
AU2020409006A1 (en) * 2019-12-18 2022-06-30 Zeno Management, Inc. Macrocyclic compounds
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
MX2017001656A (es) * 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
CR20180499A (es) * 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
CN112040944A (zh) 2020-12-04
AU2019263026B2 (en) 2022-06-30
JP2021522246A (ja) 2021-08-30
SG11202010528XA (en) 2020-11-27
AU2019263026A1 (en) 2020-12-17
WO2019211721A1 (en) 2019-11-07
MX2020011453A (es) 2020-12-07
MA52499A (fr) 2021-04-14
BR112020022020A2 (pt) 2021-02-02
EP3787620A1 (en) 2021-03-10
TW202014184A (zh) 2020-04-16
CA3097486A1 (en) 2019-11-07
US20210030718A1 (en) 2021-02-04
KR20210005182A (ko) 2021-01-13

Similar Documents

Publication Publication Date Title
ZA202202097B (en) Amino pyrimidine ssao inhibitors
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2022003930A (es) Conjugados de péptido de camptotecina.
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201991622A1 (ru) Комплексная терапия для лечения рака
AU2018278311A1 (en) IRE1 small molecule inhibitors
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
CY1123186T1 (el) Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου
MX2021007247A (es) Derivados de rapamicina.
ZA202103975B (en) Methods of treating disease with magl inhibitors
EA201891342A1 (ru) Изоиндольные соединения
EP3781148A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
MX2020011453A (es) Combinaciones para tratar el cancer.
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
MX2021008865A (es) Inhibidores de magl para usarse para tratar enfermedades antecedentes.
EA202193276A1 (ru) Способы лечения холангиокарциномы
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб